Equities

Hamilton Thorne Ltd

Hamilton Thorne Ltd

Actions
  • Price (EUR)1.49
  • Today's Change-0.02 / -1.32%
  • Shares traded1.07k
  • 1 Year change+75.29%
  • Beta--
Data delayed at least 15 minutes, as of Nov 26 2024 07:12 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Hamilton Thorne Ltd. is a provider of precision instruments, consumables, software and services to assisted reproductive technologies (ART), research, and cell biology markets. The Company markets its products and services under the Hamilton Thorne, Gynemed, Planer, Tek-Event, IVFtech, Microptic, and Embryotech Laboratories brands. It also provides an array of third-party equipment and consumables to meet customer requirements. Its branded instrument, equipment and software product lines include precision laser devices, imaging systems, incubators, laminar flow workstations, air purification systems, control rate freezers, lab monitoring systems, and micromanipulation systems. It also offers a portfolio of artificial intelligence (AI)-enabled common astronomy software applications (CASA) software and other product offerings. Its GM501 family of products provides the in vitro fertilization (IVF) lab with comprehensive cell culture media solutions.

  • Revenue in CAD (TTM)106.71m
  • Net income in CAD-2.92m
  • Incorporated2007
  • Employees--
  • Location
    Hamilton Thorne Ltd100 Cummings Ctr Ste 465eBEVERLY 01915-6143United StatesUSA
  • Phone+1 (978) 921-2050
  • Fax+1 (978) 921-0250
  • Websitehttps://www.hamiltonthorne.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.